# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian cancer

Cancer, Ovarian
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 21-30 of 2566 results.
Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Status: Recruiting
Last Changed: Mar 07, 2019
First Received: Aug 11, 2017
Disease(s): Ovarian Cancer
Intervention(s): Fostamatinib and Paclitaxel
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Influence of Chemotherapy on Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer
Status: Withdrawn
Last Changed: Aug 11, 2014
First Received: May 25, 2012
Disease(s): Ovarian Cancer
Intervention(s): Carboplatin and / or taxol chemotherapy
Locations: CHU de RENNES, Rennes, France
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients.
Status: Recruiting
Last Changed: Feb 11, 2020
First Received: Nov 09, 2018
Disease(s): Advanced Ovarian Cancer
Intervention(s): Bevacizumab, Durvalumab, Olaparib, Placebo olaparib, Durvalumab placebo, Carboplatin+Paclitaxel
Locations: Research Site, Concord, California, United States
Research Site, Foothill Ranch, California, United States
Research Site, Los Angeles, California, United States
Research Site, Oakland, California, United States
Research Site, Orange, California, United States
... and 220 other locations.
Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer
Status: Recruiting
Last Changed: Sep 04, 2018
First Received: Jul 16, 2018
Disease(s): Ovarian Cancer
Intervention(s): Apatinib
Locations: The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients
Status: Active, not recruiting
Last Changed: Feb 06, 2019
First Received: Jul 03, 2015
Disease(s): Ovarian Cancer
Intervention(s): Masitinib, Gemcitabine, Placebo
Locations: Centre hospitalo-universitaire de Beni Messous, Algiers, Algeria
Institut Sainte Catherine, Avignon, France
City Oncology Clinic, St.-Petersburg, Russian Federation
Complejo Hospitalario Universitario de Santiago, Santiago, Spain
Lviv State Oncological Regional Treatment and Diagnostic Center, Lviv, Ukraine
... and 2 other locations.
Cabazitaxel in Platinum Refractory Ovarian Cancer
Status: Terminated
Last Changed: Dec 04, 2014
First Received: Dec 11, 2012
Disease(s): Ovarian Cancer
Intervention(s): Cabazitaxel
Locations: Department of Oncology, Aalborg Hospital, Aalborg, Denmark
Herlev Hospital, Herlev, Denmark
Department of Oncology, Odense University Hospital, Odense, Denmark
Department of Oncology, Vejle Hospital, Vejle, Denmark
Restrictive or Individualized Goal-Directed Fluid Replacement Strategy in Ovarian Cancer Cytoreductive Surgery
Status: Completed
Last Changed: Jan 31, 2020
First Received: May 08, 2018
Disease(s): Ovarian Cancer
Intervention(s): EV1000(FloTrac System 4.0)
Locations: Tata Medical Centre, Kolkata, West Bengal, India
Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies
Status: Recruiting
Last Changed: Dec 20, 2019
First Received: May 09, 2019
Disease(s): Ovarian Cancer
Locations: University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)
Status: Completed
Last Changed: Jul 02, 2017
First Received: Feb 04, 2014
Disease(s): Ovarian Cancer
Intervention(s): IMAB027
Locations: UZ Brussels, Brussels, Belgium
UZ Leuven, Leuven, Belgium
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany
Universitäts-Frauenklinik (UFK) Tübingen, Tübingen, Baden-Württemberg, Germany
Universitätsklinikum Ulm, Frauenklinik, Ulm, Baden-Württemberg, Germany
... and 5 other locations.
MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
Status: Recruiting
Last Changed: Apr 10, 2019
First Received: Jan 10, 2019
Disease(s): Ovarian Cancer
Intervention(s): anti-MESO CAR-T cells, Fludarabine, Cyclophosphamide
Locations: The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China